MKKGY changes
Pick any two versions below to diff them.
- Price
- $32.27 → $33.68(+4.4%)
- Recent events
- added: Oct 19, 2026: Merck agreed to buy Silence Therapeutics, a UK biotechnology company with siRNA medicines, for $20.00 in cash per American Depositary Share. The deal has an enterprise value of $1.1 billion and an equity value of about $1.3 billion. Silence's lead medicine, divesiran, goes into Phase 3 trials for polycythemia vera, a rare blood cancer. The deal needs Silence shareholder approval, a UK court approval and regulatory approvals, and the companies expect it to close in Q1 2027. Sep 23, 2026: Bio-Techne shareholders approved the purchase by Merck at a special meeting. The US antitrust waiting period ended on September 18, 2026. The deal still needs other regulatory approvals, and Bio-Techne still expects it to close in late 2026 or early 2027. Aug 6, 2026: Merck reported Q2 2026 results. Net sales rose 3.4% to € 5.43 billion, with organic growth of 4.1%. EBITDA pre rose 9.4% to € 1.60 billion, a margin of 29.4%. EPS pre rose to € 2.16, while reported EPS fell to € 1.13 because of a hedge effect linked to the Bio-Techne purchase and higher administration costs. Life Science grew 8.0% and Electronics 11.7% organically, and Healthcare fell 3.4%. Merck raised its 2026 guidance to net sales of € 21.0 billion to € 21.8 billion and EBITDA pre of € 5.9 billion to € 6.3 billion. Jul 1, 2026: Merck announced that it will repay early, on September 9, 2026, the full € 271 million outstanding of a hybrid bond issued in 2020. Jun 25, 2026: Merck agreed to buy Bio-Techne, a US maker of life science tools, analytical technologies and consumables, for $73 per share in cash, an enterprise value of about $11.3 billion (€ 9.9 billion). The deal needs antitrust approvals and the approval of Bio-Techne shareholders, and Merck expects it to close in late 2026 or early 2027. It expects the deal to raise the EBITDA pre margin at once and to add to EPS pre from the third year after closing. Jun 18, 2026: Merck completed the purchase of Saturnus Bio, a private US biotechnology company that develops gene modulation treatments for rare inherited heart muscle diseases. May 1, 2026: Kai Beckmann became Chair of the Executive Board, after Belén Garijo's term ended in April 2026. Benjamin Hein succeeded him as CEO Electronics.